- Home
- PNRG vs TLSI Comparison
PNRG vs TLSI Comparison
Compare PNRG & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNRG | TLSI |
|---|---|---|
| Founded | 1973 | 2010 |
| Country | United States | United States |
| Employees | N/A | 110 |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.4M | 267.1M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | PNRG | TLSI |
|---|---|---|
| Price | $221.30 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 30.2K | ★ 225.9K |
| Earning Date | 04-14-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.81 | N/A |
| EPS | ★ 9.43 | N/A |
| Revenue | ★ $237,796,000.00 | N/A |
| Revenue This Year | N/A | $41.93 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | $23.03 | ★ N/A |
| Revenue Growth | ★ 79.05 | N/A |
| 52 Week Low | $126.40 | $3.42 |
| 52 Week High | $238.20 | $7.95 |
Technical Indicators
Market Signals| Indicator | PNRG | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 65.85 | 30.16 |
| Support Level | $159.14 | $3.79 |
| Resistance Level | N/A | $5.51 |
| Average True Range (ATR) | 9.05 | 0.30 |
| MACD | 0.98 | -0.07 |
| Stochastic Oscillator | 76.58 | 8.42 |
Price Performance
Historical ComparisonAbout PNRG PrimeEnergy Resources Corporation
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.